<?xml version="1.0" encoding="UTF-8"?>
<xmi:XMI xmlns:text="http:///de/fraunhofer/scai/bio/extraction/types/text.ecore" xmlns:container="http:///de/fraunhofer/scai/bio/extraction/types/text/documentelement/container.ecore" xmlns:tcas="http:///uima/tcas.ecore" xmlns:meta2="http:///de/fraunhofer/scai/bio/extraction/types/text/documentelement/meta.ecore" xmlns:xmi="http://www.omg.org/XMI" xmlns:cas="http:///uima/cas.ecore" xmlns:structure="http:///de/fraunhofer/scai/bio/extraction/types/text/documentelement/structure.ecore" xmlns:image="http:///de/fraunhofer/scai/bio/extraction/types/image.ecore" xmlns:provenance="http:///de/fraunhofer/scai/bio/extraction/types/meta/provenance.ecore" xmlns:meta="http:///de/fraunhofer/scai/bio/extraction/types/meta.ecore" xmlns:documentelement="http:///de/fraunhofer/scai/bio/extraction/types/text/documentelement.ecore" xmi:version="2.0">
    <cas:NULL xmi:id="0"/>
    <meta:Person xmi:id="1" surname="msood"/>
    <provenance:AgentProvenance xmi:id="6" user="1"/>
    <provenance:ActivityProvenance xmi:id="8" componentId="de.fraunhofer.scai.bio.uima.mysqlreader.ctgov.reader.MySQLReader" startedAtTime="439" endedAtTime="446" version="7.1-SNAPSHOT" parameters="46 50 54 58 62 66 70 74 78 82 86 453 457 90" wasAssociatedWith="6"/>
    <provenance:ActivityProvenance xmi:id="31" componentId="de.fraunhofer.scai.bio.uima.core.writer.XCasMessageWriter" startedAtTime="461" endedAtTime="468" version="7.1-SNAPSHOT" parameters="98 102 106 110 114 118" wasAssociatedWith="6"/>
    <meta:Parameter xmi:id="46" key="condition" value="false" wasGeneratedBy="8"/>
    <meta:Parameter xmi:id="50" key="recipient" value="/queue/interfacer.xmi," wasGeneratedBy="8"/>
    <meta:Parameter xmi:id="54" key="trackingNr" value="MDAzMGxvY2F0aW9uIHd3dy5zY2FpLmZyYXVuaG9mZXIuZGUvbXppbW1lcm1hbm4KMDAxY2lkZW50aWZpZXIgdGVzdCBsaWNlbnNlCjAwMjBjaWQgdGltZSA8IDIwNDItMDEtMDFUMDA6MDAKMDAyZnNpZ25hdHVyZSAJPOFDaQbvzzfyMuZOWHaYgFxTnpiSu3K6JZ1ys7Vp1go" wasGeneratedBy="8"/>
    <meta:Parameter xmi:id="58" key="QueryFile" value="etc/query" wasGeneratedBy="8"/>
    <meta:Parameter xmi:id="62" key="Query" value="Select ctgov_clinicalstudy.id,ctgov_clinicalstudy.briefTitle,ctgov_clinicalstudy.officialTitle,ctgov_clinicalstudy.briefSummary,ctgov_clinicalstudy.detaileddescription,ctgov_clinicalstudy.overallStatus,ctgov_clinicalstudy.startDate,ctgov_clinicalstudy.completionDate,ctgov_clinicalstudy.phase,ctgov_clinicalstudy.studyType,ctgov_clinicalstudy.enrollment,ctgov_clinicalstudy.criteria,ctgov_clinicalstudy.gender,ctgov_clinicalstudy.minimumAge,ctgov_clinicalstudy.maximumAge,ctgov_clinicalstudy.whyStopped,ctgov_clinicalstudy.url,ctgov_clinicalstudy.source,ctgov_clinicalstudy.firstreceivedDate,ctgov_clinicalstudy.orgStudyId,ctgov_clinicalstudy.healthyVolunteer,ctgov_clinicalstudy.lastchangedDate,ctgov_clinicalstudy.verificationDate,group_concat(DISTINCT ctgov_armgroup.armGroupLabel SEPARATOR ';;') as armGroupLabel,group_concat(DISTINCT ctgov_armgroup.armGroupType SEPARATOR ';;') as armGroupType,group_concat(DISTINCT ctgov_armgroup.description SEPARATOR ';;') as armGroupdescription,group_concat(DISTINCT ctgov_authority.authority SEPARATOR ';;') as authority,&#9;group_concat(DISTINCT ctgov_baseline.id SEPARATOR ';;') as baselineId,group_concat(DISTINCT ctgov_baselinemeasure.baselineMeasureTitle SEPARATOR ';;') as baselineMeasureTitle,group_concat(DISTINCT ctgov_baselinemeasure.description SEPARATOR ';;') as baselineDescription,group_concat(DISTINCT ctgov_baselinemeasure.unitsOfMeasure SEPARATOR ';;') as unitsOfMeasure,group_concat(DISTINCT ctgov_baselinemeasurecatgy.categoryTitle SEPARATOR ';;') as categoryTitle,group_concat(DISTINCT ctgov_baselinemeasurecatgy.baselineValue SEPARATOR ';;') as baselineValue,group_concat(DISTINCT ctgov_centralcontact.nameDegree SEPARATOR ';;') as nameDegree,group_concat(DISTINCT ctgov_condition.`condition` SEPARATOR ';;') as `condition`,group_concat(DISTINCT ctgov_condition.nct_id SEPARATOR ';;') as nct_id,group_concat(DISTINCT ctgov_design.designName SEPARATOR ';;') as designName,group_concat(DISTINCT ctgov_design.designValue SEPARATOR ';;') as designValue,group_concat(DISTINCT ctgov_intervention.interventionType SEPARATOR ';;') as interventionType,group_concat(DISTINCT ctgov_intervention.interventionName SEPARATOR ';;') as interventionName,group_concat(DISTINCT ctgov_intervention.description SEPARATOR ';;') as description,group_concat(DISTINCT ctgov_outcome.outcomeType SEPARATOR ';;') as outcomeType,group_concat(DISTINCT ctgov_outcome.outcomeTitle SEPARATOR ';;') as outcomeTitle,group_concat(DISTINCT ctgov_outcome.timeFrame SEPARATOR ';;') as timeFrame,group_concat(DISTINCT ctgov_outcome.outcomeDescription SEPARATOR ';;') as outcomeDescription,group_concat(DISTINCT ctgov_reference.citation SEPARATOR ';;') as citation,group_concat(DISTINCT ctgov_reference.pmid SEPARATOR ';;') as pmid,group_concat(DISTINCT ctgov_studyoutcome.studyOutcomesType SEPARATOR ';;') as studyOutcomesType,group_concat(DISTINCT ctgov_studyoutcome.measure SEPARATOR ';;') as measure,group_concat(DISTINCT ctgov_keyword.keyword SEPARATOR ';;') as keyword,group_concat(DISTINCT ctgov_facility.city SEPARATOR ';;') as city,group_concat(DISTINCT ctgov_facility.country SEPARATOR ';;') as country,group_concat(DISTINCT ctgov_facility.facilityName SEPARATOR ';;') as facilityName,group_concat(DISTINCT ctgov_facilitycontact.nameDegree SEPARATOR ';;') as facilityNameDegree,group_concat(DISTINCT ctgov_facilitycontact.phone SEPARATOR ';;') as phone,group_concat(DISTINCT ctgov_responsibleparty.nameTitle SEPARATOR ';;') as nameTitle,group_concat(DISTINCT ctgov_responsibleparty.responsiblePartyType SEPARATOR ';;') as partyType,group_concat(DISTINCT ctgov_responsibleparty.organization SEPARATOR ';;') as organization,group_concat(DISTINCT ctgov_secondaryid.secondaryId SEPARATOR ';;') as secondaryId,group_concat(DISTINCT ctgov_outcomeanalysis.outcome_id SEPARATOR ';;') as outcomeId,group_concat(DISTINCT ctgov_outcomeanalysis.paramType SEPARATOR ';;') as paramType,group_concat(DISTINCT ctgov_outcomeanalysis.groupsDesc SEPARATOR ';;') as groupsDesc,group_concat(DISTINCT ctgov_outcomeanalysis.pValue SEPARATOR ';;') as pValue,group_concat(DISTINCT ctgov_outcomeanalysis.pValueDesc SEPARATOR ';;') as pValueDesc,group_concat(DISTINCT ctgov_outcomemeasure.unitOfMeasure SEPARATOR ';;') as unitOfMeasure,group_concat(DISTINCT ctgov_outcomemeasure.measureType SEPARATOR ';;') as measureType, group_concat(DISTINCT ctgov_outcomemeasurectgy.outcomeValue SEPARATOR ';;') as outcomeValue from ctgov_clinicalstudy left join ctgov_armgroup on (ctgov_clinicalstudy.id=ctgov_armgroup.nct_id) left join ctgov_authority on (ctgov_clinicalstudy.id=ctgov_authority.nct_id) left join ctgov_baseline on (ctgov_clinicalstudy.id=ctgov_baseline.nct_id) left join ctgov_baselinemeasure on (ctgov_baseline.id=ctgov_baselinemeasure.rsltsBaseline_id) left join ctgov_baselinemeasurecatgy on (ctgov_baseline.id=ctgov_baselinemeasurecatgy.baseline_id) left join ctgov_centralcontact on (ctgov_clinicalstudy.id=ctgov_centralcontact.nct_id) left join ctgov_condition on (ctgov_clinicalstudy.id=ctgov_condition.nct_id) left join ctgov_design on (ctgov_clinicalstudy.id=ctgov_design.nct_id) left join ctgov_intervention on (ctgov_clinicalstudy.id=ctgov_intervention.nct_id) left join ctgov_outcome on (ctgov_clinicalstudy.id=ctgov_outcome.nct_id) left join ctgov_reference on (ctgov_clinicalstudy.id=ctgov_reference.nct_id) left join ctgov_studyoutcome on (ctgov_clinicalstudy.id=ctgov_studyoutcome.nct_id) left join ctgov_keyword on (ctgov_clinicalstudy.id=ctgov_keyword.nct_id) left join ctgov_facility on (ctgov_clinicalstudy.id=ctgov_facility.nct_id) left join ctgov_facilitycontact on (ctgov_clinicalstudy.id=ctgov_facilitycontact.nct_id) left join ctgov_responsibleparty on (ctgov_clinicalstudy.id=ctgov_responsibleparty.nct_id) left join ctgov_secondaryid on (ctgov_clinicalstudy.id=ctgov_secondaryid.nct_id) left join ctgov_outcomeanalysis on (ctgov_outcome.id=ctgov_outcomeanalysis.outcome_id) left join ctgov_outcomemeasure on (ctgov_outcome.id=ctgov_outcomemeasure.outcome_id) left join ctgov_outcomemeasurectgy on(ctgov_outcomemeasure.id = ctgov_outcomemeasurectgy.outcomeMeasure_id) where ctgov_condition.`condition` like &quot;%alzheimer%&quot; or ctgov_condition.`condition` like &quot;%mild cognitive impairment%&quot; or ctgov_condition.`condition` like &quot;%mci&quot; or ctgov_condition.`condition` like &quot;mci%&quot; or ctgov_condition.`condition` like &quot;%dementia%&quot; group by ctgov_clinicalstudy.id" wasGeneratedBy="8"/>
    <meta:Parameter xmi:id="66" key="connection" value="jdbc:mysql://delorean:3306/aetionomy" wasGeneratedBy="8"/>
    <meta:Parameter xmi:id="70" key="password" value="zcram" wasGeneratedBy="8"/>
    <meta:Parameter xmi:id="74" key="username" value="marcz" wasGeneratedBy="8"/>
    <meta:Parameter xmi:id="78" key="limit" value="10" wasGeneratedBy="8"/>
    <meta:Parameter xmi:id="82" key="offset" value="0" wasGeneratedBy="8"/>
    <meta:Parameter xmi:id="86" key="documentCollectionName" value="MZ" wasGeneratedBy="8"/>
    <meta:Parameter xmi:id="90" key="event" value="" wasGeneratedBy="8"/>
    <meta:Parameter xmi:id="94" key="inputString" value="" wasGeneratedBy="8"/>
    <meta:Parameter xmi:id="98" key="jmsBroker" value="flux" wasGeneratedBy="31"/>
    <meta:Parameter xmi:id="102" key="jmsIni" value="etc/jms.ini" wasGeneratedBy="31"/>
    <meta:Parameter xmi:id="106" key="jmsTool" value="MysqlReaderMessageDeployer (7.1-SNAPSHOT)" wasGeneratedBy="31"/>
    <meta:Parameter xmi:id="110" key="jmsSource" value="/queue/dummy" wasGeneratedBy="31"/>
    <meta:Parameter xmi:id="114" key="jmsBilling" value="creating XCAS" wasGeneratedBy="31"/>
    <meta:Parameter xmi:id="118" key="storeResult" value="" wasGeneratedBy="31"/>
    <meta:KeyValue xmi:id="122" key="license" value="MDAzMGxvY2F0aW9uIHd3dy5zY2FpLmZyYXVuaG9mZXIuZGUvbXppbW1lcm1hbm4KMDAxY2lkZW50aWZpZXIgdGVzdCBsaWNlbnNlCjAwMjBjaWQgdGltZSA8IDIwNDItMDEtMDFUMDA6MDAKMDAyZnNpZ25hdHVyZSAJPOFDaQbvzzfyMuZOWHaYgFxTnpiSu3K6JZ1ys7Vp1go"/>
    <meta:KeyValue xmi:id="126" key="entityProvenance.documentURI" value="file:/home/msood/workspace/TheInterfacer/NCT00000171"/>
    <meta:KeyValue xmi:id="130" key="unit" value=""/>
    <meta:KeyValue xmi:id="134" key="tracking-nr" value="MZ"/>
    <tcas:DocumentAnnotation xmi:id="138" sofa="425" begin="0" end="8987" language="x-unspecified"/>
    <meta:Header xmi:id="143" sofa="425" begin="0" end="0" source="National Institute on Aging (NIA)" title="Study of Melatonin: Sleep Problems in Alzheimer's Disease" authors="475 480 485 490 495 500 505 510" publicationDate="515" ISSN="NCT00000171" documentConcept="519"/>
    <provenance:EntityProvenance xmi:id="166" documentID="35075f4cf9321376e26342e34ae934bdbb609d876bcd551fd8e2b3cf30d3d679" userSuppliedID="NCT00000171" wasDerivedFrom="http://www.scai.fraunhofer.de" workflowProvenance="8 31" wasGeneratedBy="8" wasAttributedTo="6" documentCollectionName="MZ"/>
    <tcas:DocumentAnnotation xmi:id="179" sofa="432" begin="0" end="8987" language="x-unspecified"/>
    <meta2:DocumentTitle xmi:id="184" sofa="432" begin="13" end="70" wasGeneratedBy="8"/>
    <meta2:Abstract xmi:id="192" sofa="432" begin="247" end="971" wasGeneratedBy="8"/>
    <container:Section xmi:id="198" sofa="432" begin="12" end="247" wasGeneratedBy="8" title="Overview" rhetorical="Overview"/>
    <container:Section xmi:id="207" sofa="432" begin="261" end="2489" wasGeneratedBy="8" title="Description:" rhetorical="Description:"/>
    <container:Section xmi:id="216" sofa="432" begin="261" end="2489" wasGeneratedBy="8" title="Detailed Description:" rhetorical="Detailed Description:"/>
    <container:Section xmi:id="225" sofa="432" begin="993" end="2489" wasGeneratedBy="8" title="Brief Summary:" rhetorical="Brief Summary:"/>
    <container:Section xmi:id="234" sofa="432" begin="2498" end="5645" wasGeneratedBy="8" title="Criteria:" rhetorical="Criteria:"/>
    <container:Section xmi:id="243" sofa="432" begin="5660" end="5959" wasGeneratedBy="8" title="Further Study Details:" rhetorical="Further Study Details:"/>
    <container:SubSection xmi:id="252" sofa="432" begin="2518" end="4364" wasGeneratedBy="8" title="Inclusion Criteria." rhetorical="Inclusion Criteria."/>
    <container:SubSection xmi:id="261" sofa="432" begin="4383" end="5645" wasGeneratedBy="8" title="Exclusion Criteria." rhetorical="Exclusion Criteria."/>
    <structure:List xmi:id="270" sofa="432" begin="5956" end="8684" wasGeneratedBy="8" rhetorical="Additional Information:">
        <items>1. Design Information:</items>
        <items>1.1 Design Name:	Allocation;;Intervention Model;;Masking;;Primary Purpose</items>
        <items>1.2 Design Value:	Randomized;;Parallel Assignment;;Double-Blind;;Treatment</items>
        <items>2. Intervention Information:</items>
        <items>2.1 Intervention Type:	Drug</items>
        <items>2.2 Intervention Name:	Melatonin</items>
        <items>2.3 Description:	No information</items>
        <items>3. Outcome Details:</items>
        <items>3.1 Outcome Type:	No information</items>
        <items>3.2 Time Frame:	No information</items>
        <items>3.3 Outcome Title:	No information</items>
        <items>3.4 Outcome ID:	No information</items>
        <items>3.5 Outcome Description:	No information</items>
        <items>3.6 Parameter Type:	No information</items>
        <items>3.7 Group Description:	No information</items>
        <items>3.8 P Value:	No information</items>
        <items>3.9 P Value Description:	No information</items>
        <items>3.10 Unit of Measure:	No information</items>
        <items>3.11 Type of Measure:	No information</items>
        <items>3.12 Outcome Value:	No information</items>
        <items>4. Study Outcome Details:</items>
        <items>4.1 Study Outcome Type:	No information</items>
        <items>4.2 Measure:	No information</items>
        <items>5. Location Details:</items>
        <items>5.1 City:	Augusta;;Irvine;;La Jolla;;Atlanta;;Baltimore;;Jacksonville;;New York;;Kansas City;;Tampa;;New Haven;;Miami;;Springfield;;Portland;;Pittsburgh;;Philadelphia;;Rochester;;Cleveland;;Lexington;;Ann Arbor;;St. Louis;;Minneapolis;;Tucson;;Los Angeles;;Seattle;;Houston;;Dallas;;Nashville;;Pawtucket</items>
        <items>5.2 Country:	United States</items>
        <items>5.3 Facility Name:	Augusta VA Medical Center;;University of California Irvine Institute for Brain Aging and Dementia;;University of California, San Diego;;Emory University;;Johns Hopkins University;;Mayo Clinic Jacksonville;;Columbia University;;University of Kansas Medical Center;;University of South Florida;;Yale University, Alzheimer's Disease ResearchUnit;;Mount Sinai (Miami);;Southern Illinois University;;Oregon Health Sciences University;;University of Pittsburgh;;University of Pennsylvania;;University of Rochester Medical Center;;University Hospitals of Cleveland;;New York University Medical Center;;University of Kentucky;;University of Michigan;;Mayo Clinic at Rochester;;Washington University;;University of Minnesota;;University of Arizona;;University of Southern California;;University of California, Los Angeles;;University of Washington;;Baylor College of Medicine;;University of Texas;;Vanderbilt University Medical Center;;Brown University</items>
        <items>5.4 Facility Name Degree:	No information</items>
        <items>5.5 Phone:	No information</items>
        <items>6. Responsible Party Details:</items>
        <items>6.1 Name Title:	No information</items>
        <items>6.2 Party Type:	No information</items>
        <items>6.3 Organization:	No information</items>
        <items>7. Arm Group Details;</items>
        <items>7.1 Arm Group Label:	No information</items>
        <items>7.2 Arm Group Type:	No information</items>
        <items>7.3 Arm Group Description:	No information</items>
        <items>8. Baseline Measure Details:</items>
        <items>8.1 Baseline ID:	No information</items>
        <items>8.2 Baseline Measure Title:	No information</items>
        <items>8.3 Baseline Description:	No information</items>
        <items>8.4 Units of Measure:	No information</items>
        <items>8.5 Category Title:	No information</items>
        <items>8.6 Baseline Value:	No information</items>
        <items>9. Reference:</items>
    </structure:List>
    <meta2:Reference xmi:id="414" sofa="432" begin="8711" end="8986" wasGeneratedBy="8"/>
    <cas:Sofa xmi:id="425" sofaNum="1" sofaID="_InitialView" mimeType="text" sofaString="Brief Title:&#9;Study of Melatonin: Sleep Problems in Alzheimer's Disease&#10;Official Title:&#9;No information&#10;NCT-ID:&#9;NCT00000171&#10;Start Date:&#9;No information&#10;Completion Date:&#9;No information&#10;First Received Date:&#9;October 29, 1999&#10;Last Updated:&#9;June 23, 2005&#10;Brief Summary:&#10;This protocol is a multicenter clinical trial of melatonin for sleep disturbances associated with Alzheimer's disease (AD). Frequent nocturnal awakening is a common behavioral symptom of AD. Nighttime wandering and agitated behavior may result in injuries and sleep disruption for caregivers. Alternatives are sorely needed to the currently available sleep medications that have marginal efficacy and serious side effects. Melatonin is a naturally occurring hormone secreted by the pineal gland. It has soporific effects with oral administration and is well tolerated. It enhances sleep in normal older people. Melatonin also may help sleep disturbances associated with AD; however, this remains to be proven.&#10;Detailed Description:&#10;In Alzheimer's disease , sleep disruption is one of the most common behavioral problems, occurring in 45 percent of patients. These nocturnal awakenings and agitation lead to considerable burden for caregivers and frequently lead families to the decision of nursing home placement. The proposed study is a randomized, double blind, parallel group, placebo controlled, clinical trial. Placebo will be compared with two doses of melatonin: a 2.5 mg, slow- release preparation and a 10 mg immediate release preparation. One hundred and fifty community-residing AD patients with disrupted sleep will be recruited. Included subjects will meet NINCDS-ADRDA criteria for probable AD. Prior to study entry, disrupted sleep will be documented by clinical history and by 1 to 2 weeks of recording using wrist activity monitors. The treatment period will last 8 weeks. Rest/activity patterns will be recorded by wrist activity monitors. The primary outcome measure will be the change in nocturnal sleep time from baseline to the end of the treatment phase. Other outcomes also will be examined, including the time awake after sleep onset, sleep latency, sleep efficiency, daytime agitation, and changes in cognition. The relative effectiveness of high and low dose melatonin will be assessed. Adverse events and side effects will be compared by treatment. This study should provide the data necessary to determine whether melatonin is a safe and effective treatment for disrupted sleep associated with AD.&#10;Criteria:&#10;Inclusion Criteria.&#10; - Patients must meet NINCDS-ADRDA criteria for probable Alzheimer's disease (AD). Patients must have disrupted sleep, documented by clinical history and by 1 to 2 weeks of recording using wrist activity monitors.&#10; - A diagnosis of probable AD.&#10; - MMSE score 0-26.&#10; - Hachinski Ischemia Scale score less than or equal to 4.&#10; - A 2-week history of two or more sleep disorder behaviors, occurring at least once weekly, as reported by the caregiver on the Sleep Disorder Inventory.&#10; - CT or MRI since the onset of memory problems showing no more than one lacunar infarct in a non-strategic area and no clinical events suggestive of stroke or other intracranial disease since the CT or MRI.&#10; - Physically acceptable for study as confirmed by medical history and exam, clinical laboratory results, and EKG.&#10; - Actigraph evidence of a mean nocturnal sleep time of less than 7 hours per night (at least 5 nights of complete actigraph data must be collected over a single week.&#10; - Stable home situation with no planned move during the 13-week investigational period.&#10; - Residing with responsible spouse, family member, or professional caregiver who is present during the night and will agree to assume the role of the principal caregiver for the 13-week protocol, including arranging transport for the patient to and from the investigators' clinic, answering questions regarding the patient's condition, and assuming responsibility for medication and actigraph procedures.&#10; - Ability to ingest oral medication and participate in all scheduled evaluations.&#10; - Six grades of education or work history sufficient to exclude mental retardation.&#10; - 55 years of age or older.&#10; - Hamilton Depression Rating Scale score of 15 or less.&#10; - Stable medication (dose and type) for non-excluded concurrent medical conditions for 4 weeks prior to the screening visit. Exclusion Criteria.&#10; - Sleep disturbance is acute (within the last 2 weeks).&#10; - Sleep disturbance is associated with an acute illness with delirium.&#10; - Clinically significant movement disorder that would interfere with the actigraph readings.&#10; - Not having a mobile upper extremity to which to attach an actigraph.&#10; - Severe agitation.&#10; - Pain syndrome affecting sleep.&#10; - Unstable medical condition.&#10; - Use of investigational or unapproved medications within 4 weeks of the screening visit.&#10; - Patient unwilling to maintain caffeine abstinence after 2:00 pm for the duration of the protocol.&#10; - Patient unwilling to comply with the maximum limit of two alcoholic drinks per day, and only one alcoholic drink after 6:00 pm for the duration of the protocol.&#10; - Use of melatonin within 2 weeks of screening visit.&#10; - Clinically significant abnormal laboratory findings that have not been approved by the Project Director.&#10; - Residing in a facility without a consistent caregiver present during the night who can function as the primary informant.&#10; - Caregiver deemed too unreliable to supervise the wearing of the actigraph, to maintain the sleep diary, or to bring the patient to the scheduled visits.&#10; - Autoimmune disease, such as rheumatoid arthritis and polymyalgia rheumatica.&#10;Overall Status:&#9;Completed&#10;Phase:&#9;Phase 3&#10;Study Type:&#9;Interventional&#10;Why Stopped:&#9;No information&#10;Healthy Volunteer:&#9;No&#10;Enrollment:&#9;No information&#10;Gender:&#9;Both&#10;Minimum Age:&#9;55 Years&#10;Maximum Age:&#9;N/A&#10;&#10;Contact Name:&#9;No information&#10;Other ID's:&#9;Secondary ID: 3U01AG10483-08S2,Org Study ID: IA0006&#10;PubMedID:&#9;14655926&#10;&#10;1. Design Information:&#10;1.1 Design Name:&#9;Allocation;;Intervention Model;;Masking;;Primary Purpose&#10;1.2 Design Value:&#9;Randomized;;Parallel Assignment;;Double-Blind;;Treatment&#10;&#10;2. Intervention Information:&#10;2.1 Intervention Type:&#9;Drug&#10;2.2 Intervention Name:&#9;Melatonin&#10;2.3 Description:&#9;No information&#10;&#10;3. Outcome Details:&#10;3.1 Outcome Type:&#9;No information&#10;3.2 Time Frame:&#9;No information&#10;3.3 Outcome Title:&#9;No information&#10;3.4 Outcome ID:&#9;No information&#10;3.5 Outcome Description:&#9;No information&#10;3.6 Parameter Type:&#9;No information&#10;3.7 Group Description:&#9;No information&#10;3.8 P Value:&#9;No information&#10;3.9 P Value Description:&#9;No information&#10;3.10 Unit of Measure:&#9;No information&#10;3.11 Type of Measure:&#9;No information&#10;3.12 Outcome Value:&#9;No information&#10;&#10;4. Study Outcome Details:&#10;4.1 Study Outcome Type:&#9;No information&#10;4.2 Measure:&#9;No information&#10;&#10;5. Location Details:&#10;5.1 City:&#9;Augusta;;Irvine;;La Jolla;;Atlanta;;Baltimore;;Jacksonville;;New York;;Kansas City;;Tampa;;New Haven;;Miami;;Springfield;;Portland;;Pittsburgh;;Philadelphia;;Rochester;;Cleveland;;Lexington;;Ann Arbor;;St. Louis;;Minneapolis;;Tucson;;Los Angeles;;Seattle;;Houston;;Dallas;;Nashville;;Pawtucket&#10;5.2 Country:&#9;United States&#10;5.3 Facility Name:&#9;Augusta VA Medical Center;;University of California Irvine Institute for Brain Aging and Dementia;;University of California, San Diego;;Emory University;;Johns Hopkins University;;Mayo Clinic Jacksonville;;Columbia University;;University of Kansas Medical Center;;University of South Florida;;Yale University, Alzheimer's Disease ResearchUnit;;Mount Sinai (Miami);;Southern Illinois University;;Oregon Health Sciences University;;University of Pittsburgh;;University of Pennsylvania;;University of Rochester Medical Center;;University Hospitals of Cleveland;;New York University Medical Center;;University of Kentucky;;University of Michigan;;Mayo Clinic at Rochester;;Washington University;;University of Minnesota;;University of Arizona;;University of Southern California;;University of California, Los Angeles;;University of Washington;;Baylor College of Medicine;;University of Texas;;Vanderbilt University Medical Center;;Brown University&#10;5.4 Facility Name Degree:&#9;No information&#10;5.5 Phone:&#9;No information&#10;&#10;6. Responsible Party Details:&#10;6.1 Name Title:&#9;No information&#10;6.2 Party Type:&#9;No information&#10;6.3 Organization:&#9;No information&#10;&#10;7. Arm Group Details;&#10;7.1 Arm Group Label:&#9;No information&#10;7.2 Arm Group Type:&#9;No information&#10;7.3 Arm Group Description:&#9;No information&#10;&#10;8. Baseline Measure Details:&#10;8.1 Baseline ID:&#9;No information&#10;8.2 Baseline Measure Title:&#9;No information&#10;8.3 Baseline Description:&#9;No information&#10;8.4 Units of Measure:&#9;No information&#10;8.5 Category Title:&#9;No information&#10;8.6 Baseline Value:&#9;No information&#10;&#10;9. Reference:&#10;9.1 Citation&#9;Singer C, Tractenberg RE, Kaye J, Schafer K, Gamst A, Grundman M, Thomas R, Thal LJ; Alzheimer's Disease Cooperative Study. A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease. Sleep. 2003 Nov 1;26(7):893-901.Pubmed PMID 14655926&#10;"/>
    <cas:Sofa xmi:id="432" sofaNum="2" sofaID="DocumentView" mimeType="text" sofaString="Brief Title:&#9;Study of Melatonin: Sleep Problems in Alzheimer's Disease&#10;Official Title:&#9;No information&#10;NCT-ID:&#9;NCT00000171&#10;Start Date:&#9;No information&#10;Completion Date:&#9;No information&#10;First Received Date:&#9;October 29, 1999&#10;Last Updated:&#9;June 23, 2005&#10;Brief Summary:&#10;This protocol is a multicenter clinical trial of melatonin for sleep disturbances associated with Alzheimer's disease (AD). Frequent nocturnal awakening is a common behavioral symptom of AD. Nighttime wandering and agitated behavior may result in injuries and sleep disruption for caregivers. Alternatives are sorely needed to the currently available sleep medications that have marginal efficacy and serious side effects. Melatonin is a naturally occurring hormone secreted by the pineal gland. It has soporific effects with oral administration and is well tolerated. It enhances sleep in normal older people. Melatonin also may help sleep disturbances associated with AD; however, this remains to be proven.&#10;Detailed Description:&#10;In Alzheimer's disease , sleep disruption is one of the most common behavioral problems, occurring in 45 percent of patients. These nocturnal awakenings and agitation lead to considerable burden for caregivers and frequently lead families to the decision of nursing home placement. The proposed study is a randomized, double blind, parallel group, placebo controlled, clinical trial. Placebo will be compared with two doses of melatonin: a 2.5 mg, slow- release preparation and a 10 mg immediate release preparation. One hundred and fifty community-residing AD patients with disrupted sleep will be recruited. Included subjects will meet NINCDS-ADRDA criteria for probable AD. Prior to study entry, disrupted sleep will be documented by clinical history and by 1 to 2 weeks of recording using wrist activity monitors. The treatment period will last 8 weeks. Rest/activity patterns will be recorded by wrist activity monitors. The primary outcome measure will be the change in nocturnal sleep time from baseline to the end of the treatment phase. Other outcomes also will be examined, including the time awake after sleep onset, sleep latency, sleep efficiency, daytime agitation, and changes in cognition. The relative effectiveness of high and low dose melatonin will be assessed. Adverse events and side effects will be compared by treatment. This study should provide the data necessary to determine whether melatonin is a safe and effective treatment for disrupted sleep associated with AD.&#10;Criteria:&#10;Inclusion Criteria.&#10; - Patients must meet NINCDS-ADRDA criteria for probable Alzheimer's disease (AD). Patients must have disrupted sleep, documented by clinical history and by 1 to 2 weeks of recording using wrist activity monitors.&#10; - A diagnosis of probable AD.&#10; - MMSE score 0-26.&#10; - Hachinski Ischemia Scale score less than or equal to 4.&#10; - A 2-week history of two or more sleep disorder behaviors, occurring at least once weekly, as reported by the caregiver on the Sleep Disorder Inventory.&#10; - CT or MRI since the onset of memory problems showing no more than one lacunar infarct in a non-strategic area and no clinical events suggestive of stroke or other intracranial disease since the CT or MRI.&#10; - Physically acceptable for study as confirmed by medical history and exam, clinical laboratory results, and EKG.&#10; - Actigraph evidence of a mean nocturnal sleep time of less than 7 hours per night (at least 5 nights of complete actigraph data must be collected over a single week.&#10; - Stable home situation with no planned move during the 13-week investigational period.&#10; - Residing with responsible spouse, family member, or professional caregiver who is present during the night and will agree to assume the role of the principal caregiver for the 13-week protocol, including arranging transport for the patient to and from the investigators' clinic, answering questions regarding the patient's condition, and assuming responsibility for medication and actigraph procedures.&#10; - Ability to ingest oral medication and participate in all scheduled evaluations.&#10; - Six grades of education or work history sufficient to exclude mental retardation.&#10; - 55 years of age or older.&#10; - Hamilton Depression Rating Scale score of 15 or less.&#10; - Stable medication (dose and type) for non-excluded concurrent medical conditions for 4 weeks prior to the screening visit. Exclusion Criteria.&#10; - Sleep disturbance is acute (within the last 2 weeks).&#10; - Sleep disturbance is associated with an acute illness with delirium.&#10; - Clinically significant movement disorder that would interfere with the actigraph readings.&#10; - Not having a mobile upper extremity to which to attach an actigraph.&#10; - Severe agitation.&#10; - Pain syndrome affecting sleep.&#10; - Unstable medical condition.&#10; - Use of investigational or unapproved medications within 4 weeks of the screening visit.&#10; - Patient unwilling to maintain caffeine abstinence after 2:00 pm for the duration of the protocol.&#10; - Patient unwilling to comply with the maximum limit of two alcoholic drinks per day, and only one alcoholic drink after 6:00 pm for the duration of the protocol.&#10; - Use of melatonin within 2 weeks of screening visit.&#10; - Clinically significant abnormal laboratory findings that have not been approved by the Project Director.&#10; - Residing in a facility without a consistent caregiver present during the night who can function as the primary informant.&#10; - Caregiver deemed too unreliable to supervise the wearing of the actigraph, to maintain the sleep diary, or to bring the patient to the scheduled visits.&#10; - Autoimmune disease, such as rheumatoid arthritis and polymyalgia rheumatica.&#10;Overall Status:&#9;Completed&#10;Phase:&#9;Phase 3&#10;Study Type:&#9;Interventional&#10;Why Stopped:&#9;No information&#10;Healthy Volunteer:&#9;No&#10;Enrollment:&#9;No information&#10;Gender:&#9;Both&#10;Minimum Age:&#9;55 Years&#10;Maximum Age:&#9;N/A&#10;&#10;Contact Name:&#9;No information&#10;Other ID's:&#9;Secondary ID: 3U01AG10483-08S2,Org Study ID: IA0006&#10;PubMedID:&#9;14655926&#10;&#10;1. Design Information:&#10;1.1 Design Name:&#9;Allocation;;Intervention Model;;Masking;;Primary Purpose&#10;1.2 Design Value:&#9;Randomized;;Parallel Assignment;;Double-Blind;;Treatment&#10;&#10;2. Intervention Information:&#10;2.1 Intervention Type:&#9;Drug&#10;2.2 Intervention Name:&#9;Melatonin&#10;2.3 Description:&#9;No information&#10;&#10;3. Outcome Details:&#10;3.1 Outcome Type:&#9;No information&#10;3.2 Time Frame:&#9;No information&#10;3.3 Outcome Title:&#9;No information&#10;3.4 Outcome ID:&#9;No information&#10;3.5 Outcome Description:&#9;No information&#10;3.6 Parameter Type:&#9;No information&#10;3.7 Group Description:&#9;No information&#10;3.8 P Value:&#9;No information&#10;3.9 P Value Description:&#9;No information&#10;3.10 Unit of Measure:&#9;No information&#10;3.11 Type of Measure:&#9;No information&#10;3.12 Outcome Value:&#9;No information&#10;&#10;4. Study Outcome Details:&#10;4.1 Study Outcome Type:&#9;No information&#10;4.2 Measure:&#9;No information&#10;&#10;5. Location Details:&#10;5.1 City:&#9;Augusta;;Irvine;;La Jolla;;Atlanta;;Baltimore;;Jacksonville;;New York;;Kansas City;;Tampa;;New Haven;;Miami;;Springfield;;Portland;;Pittsburgh;;Philadelphia;;Rochester;;Cleveland;;Lexington;;Ann Arbor;;St. Louis;;Minneapolis;;Tucson;;Los Angeles;;Seattle;;Houston;;Dallas;;Nashville;;Pawtucket&#10;5.2 Country:&#9;United States&#10;5.3 Facility Name:&#9;Augusta VA Medical Center;;University of California Irvine Institute for Brain Aging and Dementia;;University of California, San Diego;;Emory University;;Johns Hopkins University;;Mayo Clinic Jacksonville;;Columbia University;;University of Kansas Medical Center;;University of South Florida;;Yale University, Alzheimer's Disease ResearchUnit;;Mount Sinai (Miami);;Southern Illinois University;;Oregon Health Sciences University;;University of Pittsburgh;;University of Pennsylvania;;University of Rochester Medical Center;;University Hospitals of Cleveland;;New York University Medical Center;;University of Kentucky;;University of Michigan;;Mayo Clinic at Rochester;;Washington University;;University of Minnesota;;University of Arizona;;University of Southern California;;University of California, Los Angeles;;University of Washington;;Baylor College of Medicine;;University of Texas;;Vanderbilt University Medical Center;;Brown University&#10;5.4 Facility Name Degree:&#9;No information&#10;5.5 Phone:&#9;No information&#10;&#10;6. Responsible Party Details:&#10;6.1 Name Title:&#9;No information&#10;6.2 Party Type:&#9;No information&#10;6.3 Organization:&#9;No information&#10;&#10;7. Arm Group Details;&#10;7.1 Arm Group Label:&#9;No information&#10;7.2 Arm Group Type:&#9;No information&#10;7.3 Arm Group Description:&#9;No information&#10;&#10;8. Baseline Measure Details:&#10;8.1 Baseline ID:&#9;No information&#10;8.2 Baseline Measure Title:&#9;No information&#10;8.3 Baseline Description:&#9;No information&#10;8.4 Units of Measure:&#9;No information&#10;8.5 Category Title:&#9;No information&#10;8.6 Baseline Value:&#9;No information&#10;&#10;9. Reference:&#10;9.1 Citation&#9;Singer C, Tractenberg RE, Kaye J, Schafer K, Gamst A, Grundman M, Thomas R, Thal LJ; Alzheimer's Disease Cooperative Study. A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease. Sleep. 2003 Nov 1;26(7):893-901.Pubmed PMID 14655926&#10;"/>
    <meta:DateTime xmi:id="439" day="20" month="4" year="2016" hour="15" minute="49" second="23"/>
    <meta:DateTime xmi:id="446" day="20" month="4" year="2016" hour="15" minute="49" second="23"/>
    <meta:Parameter xmi:id="453" key="license" value="" wasGeneratedBy="8"/>
    <meta:Parameter xmi:id="457" key="recipients" value="" wasGeneratedBy="8"/>
    <meta:DateTime xmi:id="461" day="20" month="4" year="2016" hour="15" minute="49" second="23"/>
    <meta:DateTime xmi:id="468" day="20" month="4" year="2016" hour="15" minute="49" second="23"/>
    <meta:Person xmi:id="475" surname="C" forename="Singer"/>
    <meta:Person xmi:id="480" surname="RE" forename="Tractenberg"/>
    <meta:Person xmi:id="485" surname="J" forename="Kaye"/>
    <meta:Person xmi:id="490" surname="K" forename="Schafer"/>
    <meta:Person xmi:id="495" surname="A" forename="Gamst"/>
    <meta:Person xmi:id="500" surname="M" forename="Grundman"/>
    <meta:Person xmi:id="505" surname="R" forename="Thomas"/>
    <meta:Person xmi:id="510" surname="LJ" forename="Thal"/>
    <meta:Date xmi:id="515" day="29" month="10" year="1999"/>
    <meta:Concept xmi:id="519" prefLabel="525" identifier="NCT00000171" identifierSource="clinicaltrials.gov"/>
    <meta:Label xmi:id="525" value="ctgov:NCT00000171"/>
    <cas:View sofa="425" members="1 6 8 31 46 50 54 58 62 66 70 74 78 82 86 90 94 98 102 106 110 114 118 122 126 130 134 138 143 166"/>
    <cas:View sofa="432" members="179 184 192 198 207 216 225 234 243 252 261 270 414"/>
</xmi:XMI>
